Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Non-Current Assets: 2023-2024

Historic Non-Current Assets for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Dec 2024 value amounting to $61.3 million.

  • Monte Rosa Therapeutics' Non-Current Assets fell 9.16% to $58.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.0 million, marking a year-over-year decrease of 9.16%. This contributed to the annual value of $61.3 million for FY2024, which is 9.25% down from last year.
  • Monte Rosa Therapeutics' Non-Current Assets amounted to $61.3 million in FY2024, which was down 9.25% from $67.5 million recorded in FY2023.
  • In the past 5 years, Monte Rosa Therapeutics' Non-Current Assets ranged from a high of $67.5 million in FY2023 and a low of $61.3 million during FY2024.
  • For the 2-year period, Monte Rosa Therapeutics' Non-Current Assets averaged around $64.4 million, with its median value being $64.4 million (2023).
  • Data for Monte Rosa Therapeutics' Non-Current Assets shows a maximum YoY dropped of 9.25% (in 2024) over the last 5 years.
  • Monte Rosa Therapeutics' Non-Current Assets (Yearly) stood at $67.5 million in 2023, then dropped by 9.25% to $61.3 million in 2024.